The report "Global Migraine Drugs Market, By Treatment (Abortive Or Acute (Triptans, Ergot Alkaloids, and Anti-Nausea Medications) and Prophylactic Or Preventive (Botulinum Toxin, Topiramate, And Glucocorticoids)), By Route of Administration (Oral, Injectable, and Others (Nasal Spray and Transdermal Patch), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies), and Region - Global Forecast to 2029" Global migraine drugs market is projected to grow from US$ 2.2 billion in 2020 to US$ 8.3 billion by 2029. Increasing incidences of migraine attack will increase demand for antimigraine drugs across the globe is major factor driving the global migraine drugs market. Furthermore, rising R&D activities for drug development, coupled with growing manufactures launches antimigraine drug boosts the global migraine drug market.
Key Highlights:
• In September 2018, Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) have approved Emgality (galcanezumab-gnlm) 120 mg injection for the preventive treatment of migraine in adults.
• On August 2018, Novartis Pharmaceuticals Canada Inc announced that Health Canada has approved Aimovig (erenumab) for the prevention of migraine in adults who have at least four migraine days per month.
Key Market Insights from the report:
The global migraine drugs market accounted for US$ 2.2 billion in 2020 and is projected to register a moderate CAGR of 15.7 % over the forecast period. The market report has been segmented on the basis of treatment, route of administration, distribution channel, and region.
• By treatment, the global migraine drugs market is segmented into abortive or acute and prophylactic or preventive. Abortive or acute sub-segment is categorized into triptans, ergot alkaloids, and anti-nausea medications. Further, prophylactic or preventive sub-segment is bifurcated into botulinum toxin, topiramate, and glucocorticoids.
• By route of administration, the global migraine drugs market is classified into oral, injectable, and others. Others route of administration sub-segment is nasal spray and transdermal patch.
• By distribution channel, the global migraine drugs market is categorized into retail pharmacies, hospital pharmacies, and online pharmacies.
• By region, North America migraine drugs market is expected to account for major revenue share in global migraine drugs market, followed by other regions. This is attributed to rising penetration of migraine in the countries of the North America region. The Asia Pacific migraine drugs market is emerging market in the global migraine drugs market in 2018.
To know the upcoming trends and insights prevalent in this market, click the link below:
Links
https://www.prophecymarketinsights.com/market_insight/Global-Migrai...
The prominent player operating in the global migraine drugs market includes Pfizer Inc, GlaxoSmithKline plc, Allergan plc, Amgen Inc, Eli Lilly and Company, Teva Pharmaceuticals USA, Inc, Biohaven Pharmaceutical Holding Company Ltd, Johnson & Johnson, Novartis Pharmaceuticals Canada Inc., and Alembic Pharmaceuticals Limited.
Contact Us:
Sales
Prophecy Market Insights
Email- [email protected]